Pilot Clinical Study of FruiteX-B®

New Pilot Clinical Study Shows FruiteX-B® Calcium Fructoborate Improves WOMAC and McGill Scores, Improves Vitamin D levels, and Helps Fight Inflammation in Subjects with Knee Osteoarthritis

“FruiteX-B® group unanimously requested additional product at the conclusion of the study.”

 February 21, 2012 MOMENCE, IL – FutureCeuticals, Inc. today announced publication of the results of a successful pilot clinical study on FruiteX-B® Calcium Fructoborate, a patented plant mineral complex. The double-blind, placebo-controlled study examined the effects of FruiteX-B® supplementation during fourteen days on subjects with minor knee osteoarthritis as diagnosed by CT scan. Subjective testing measures included the widely-used Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the McGill Pain Questionnaire. Blood levels of two markers commonly associated with arthritis, C-Reactive Protein (“CRP”, a well-known general inflammatory marker), and 1,25-Dihydroxy Vitamin D (“1,25(OH)” the biologically active form of vitamin D), were also measured.

WOMAC and McGill results indicated that subjects in the FruiteX-B® group experienced significant improvements in pain, stiffness, and physical function after only seven days of supplementation. By day fourteen, WOMAC and McGill scores improved by 29% and 14% respectively.

Testing on CRP and 1,25(OH) Vitamin D also revealed exceptional results. CRP was reduced by up to 37% compared to baseline levels (established prior to treatment). Blood levels of endogenous 1,25(OH) Vitamin D increased more than 19% on average compared to baseline levels.

“The new study builds on our strong body of clinical data for FruiteX-B® and underscores the product’s capacity as a “fast acting” supplement for improving flexibility and relieving discomfort associated with Osteoarthritis”, said Hartley Pond, FutureCeuticals’ Vice President of Sales. “Perhaps the best testament to the product’s appeal, subjects in the FruiteX-B® group unanimously requested additional product at the conclusion of the study.”

Source: American Journal of Biomedical Sciences, 2012, doi: 10.5099/aj120200111

Study: Short-term Intake of Calcium Fructoborate Improves WOMAC and McGill Scores and Beneficially Modulates Biomarkers Associated with Knee Osteoarthritis: A Pilot Clinical Double-blinded Placebo-controlled Study.

Authors: Tania Reyes-Izquierdo, Boris Nemzer, Ana Elizabeth Gonzalez , Qing Zhou, Ruby Argumedo, Cynthia Shu, and Zb Pietrzkowski.

About FruiteX-B® Calcium Fructoborate

FruiteX-B® Calcium Fructoborate, a patented plant mineral complex, is a significant nutritional breakthrough for joint and bone support. Extensive and ongoing research shows FruiteX-B® beneficially modulates biotargets associated with joint degeneration and inflammation. FruiteX-B® Calcium Fructoborate is manufactured under US Patent #5,962,049 and issued and pending foreign patents and is available exclusively from VDF FutureCeuticals, Inc. 

About FutureCeuticals, Inc.

FutureCeuticals, Inc. is a vertically integrated functional food ingredient, product development, and bioanalytical research and discovery company with 700 conventional and 500 certified organic acres of farm land and facilities in Illinois, Wisconsin, California, and Europe.

FutureCeuticals is a voting member of the Council for Responsible Nutrition, a voting member of the International Probiotics Association, and a supporter of the American Botanical Council.